590d46bc-3db8-4e22-8550-b3e4ba0affba
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 79
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.450
- G2M_CHECKPOINT+0.370
- MITOTIC_SPINDLE+0.360
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.350
- UV_RESPONSE_DN+0.330
- PROTEIN_SECRETION+0.310
- INTERFERON_GAMMA_RESPONSE+0.300
- INFLAMMATORY_RESPONSE+0.290
- ANDROGEN_RESPONSE+0.270
- HYPOXIA+0.270
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.320
- DNA_REPAIR-0.300
- MYC_TARGETS_V2-0.260
- MYC_TARGETS_V1-0.230
- WNT_BETA_CATENIN_SIGNALING-0.230
- UV_RESPONSE_UP-0.220
- PEROXISOME-0.200
- PANCREAS_BETA_CELLS-0.150
- PI3K_AKT_MTOR_SIGNALING-0.120
- APICAL_SURFACE-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2796 | Med | Medulloblastoma | 0.799 |
| 2 | MDT-AP-3280 | Med | Medulloblastoma | 0.793 |
| 3 | TCGA-GV-A3QG-01A-11R-A220-07 | — | — | 0.781 |
| 4 | TCGA-A1-A0SI-01A-11R-A144-07 | — | C | 0.774 |
| 5 | MDT-AP-3264 | Med | Medulloblastoma | 0.772 |
| 6 | BS_0SCXXM6N | low-grade glioma | — | 0.764 |
| 7 | TCGA-55-6712-01A-11R-1858-07 | — | cohortA1 | 0.763 |
| 8 | BS_PRAEF32W | EPN | Posterior Fossa EPN | 0.758 |
| 9 | MDT-AP-2990 | Med | Medulloblastoma | 0.757 |
| 10 | TCGA-AR-A250-01A-31R-A169-07 | — | C | 0.756 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.450 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.370 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.360 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.350 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.330 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.310 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.290 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.270 | Inavolisib | — uncovered |
| HYPOXIA | 0.270 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.270 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.250 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.250 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.220 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.210 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.210 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.210 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.200 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.190 | Inavolisib | — uncovered |
| MYOGENESIS | 0.180 | Inavolisib | — uncovered |